---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-066545"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:19:27.124046+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agenus closes $75M sale of royalty and milestone rights to Ligand

## Summary
- Received $75M on May 30, 2024, for sale of milestone and royalty rights to Ligand Pharmaceuticals.
- Sold 31.875% of development/regulatory/commercial milestone payments under five license agreements with BMS, Incyte, Merck, UroGen, Gilead.
- Sold 18.75% of royalties from those agreements and 2.625% synthetic royalty on botensilimab/balstilimab net sales.
- Transaction closed May 29, 2024; proceeds net of certain expenses.

## SEC filing metadata
- accession: 0000950170-24-066545
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000095017024066545/0000950170-24-066545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000095017024066545/agen-20240529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-066545
- JSON: https://secwatch.observer/filing/0000950170-24-066545.json
- Plain text: https://secwatch.observer/filing/0000950170-24-066545.txt

## Key facts
- M&A Transactions
  AGENUS INC completed a disposition involving Ligand Pharmaceuticals Incorporated for $75 million (closed 2024-05-29).
  - Action: disposition
  - Counterparty: Ligand Pharmaceuticals Incorporated
  - Consideration: $75 million
  - Closing: 2024-05-29
  source text: On May 29, 2024, the transactions contemplated by the Purchase Agreement closed. Pursuant to the Purchase Agreement, on May 30, 2024, Agenus received consideration of $75 million, less certain reimbursable expenses upon the completion of the sale to Ligand of the following assets: (i) 31.875% of the development, regulatory and commercial milestone
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000095017024066545/0000950170-24-066545-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.